Skip to main content
. 2017 Aug 3;2(15):e91588. doi: 10.1172/jci.insight.91588

Figure 4. Treatment with TGF-β NAb, losartan, or MEKi improves load-induced cardiac decompensation in Fbn1C1039G/+ hearts, despite persistent load.

Figure 4

(A) Temporal changes of cardiac dimensions and function of Fbn1C1039G/+ hearts after TAC, with treatment arms. Fbn1+/+, blue circle with solid line; Fbn1C1039G/+, red square with solid line; Fbn1C1039G/+ with TGF-β NAb treatment, orange triangle with dotted line; Fbn1C1039G/+ with losartan (Los) treatment, green diamond with dotted line; Fbn1C1039G/+ with MEK1/2 inhibitor (MEKi) treatment, purple circle with dotted line. Early time point, 1 week after TAC; mid time point, 2–4 weeks after TAC; end time point, 3–5 weeks after TAC. EDD, end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening; LV mass, left ventricular mass; BL, baseline. Comparison pairs shown in brackets on right side of respective panel. n ≥ 5 per group. (B) Representative M-mode echocardiograms at end time point, Fbn1C1039G/+ sham vs. TAC groups, with and without treatment. (C) Summary quantification of heart weight normalized to tibia length (HW/TL). n ≥ 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Tukey’s correction.